Porto, Portugal
+351 960 245 977
fbnsantos@fbnsantos.com

Category: Corindus Vascular Robotics

Robotics | IoT

Robotics investments February 2019

Robotics investments totaled at least $4.3 billion in February 2019 in a steep increase from January, which had about $1.4 billion. In addition, companies reported approximately $3.9 billion worth of acquisitions this past month. Any political or economic jitters have not yet harmed the mood for robot deals. The Robotic Industries Association noted yesterday that robot…

The post Robotics investments February 2019 appeared first on The Robot Report.

Corindus submits CorPath GRX to FDA for robotic neurovascular interventions

Corindus Vascular Robotics this week said it applied to the U.S. Food and Drug Administration for premarket clearance to use its CorPath GRX robotic surgical platform in neurovascular interventions. The Waltham, Mass.-based company has already received FDA clearance for percutaneous coronary interventions (PCI), which it won in 2016, and for peripheral vascular interventions (PVI), which it won last…

The post Corindus submits CorPath GRX to FDA for robotic neurovascular interventions appeared first on The Robot Report.

Corindus CorPath GRX surgical robot receives clearance in Japan

Corindus Vascular Robotics has won clearance from Japan’s Pharmaceutical and Medical Device Agency for its CorPath GRX robotic surgical device. The CorPath GRX vascular robotics platform is designed to assist cardiologists in performing percutaneous coronary interventions (PCI) procedures, including angioplasty and stent placement. Japan is one of the largest markets in the world for PCIs, according to…

The post Corindus CorPath GRX surgical robot receives clearance in Japan appeared first on The Robot Report.

Corindus raises $25M to commercialize CorPath GRX surgical robot

Corindus Vascular Robotics inked a private placement deal worth $25 million through the offering of newly-designated Series A convertible preferred stock, with funds slated to support global commercialization of its CorPath GRX robotic surgical system. The Waltham, Mass.-based company will issue shares of Series A convertible preferred stock convertible into 20 million shares of common stock…

The post Corindus raises $25M to commercialize CorPath GRX surgical robot appeared first on The Robot Report.

FDA Clears Software for Corindus CorPath GRX Surgical Robot

Corindus Vascular Robotics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for its CorPath GRX platform. Called “Rotate on Retract” (RoR), the proprietary software feature is the first automated robotic movement in the technIQ Series for the CorPath GRX platform. It allows the operator…

The post FDA Clears Software for Corindus CorPath GRX Surgical Robot appeared first on The Robot Report.

Corindus joins with Mayo Clinic in study of tele-robotic stenting

Corindus Vascular Robotics (OTC:CVRS) said today it is working with the Mayo Clinic to launch preclinical studies exploring the use of telestenting, a robotic treatment for percutaneous coronary interventions which can be operated by physicians in remote locations. The Waltham, Mass.-based surgical robotics company said that there is a global shortage of PCI-capable operators, and that telestenting…

The post Corindus joins with Mayo Clinic in study of tele-robotic stenting appeared first on The Robot Report.

Corindus touts 1st Corpath GRX system installation outside the US

Corindus Vascular Robotics (OTC:CVRS) today touted the first commercial installation of its CorPath GRx robotic surgical system outside of the US. The CorPath GRX platform, a robot-assisted system for percutaneous coronary interventions such as stenting, was purchased and installed at the Ahmedabad, India’s Apex Heart Institute, the Waltham, Mass.-based company said. Corindus said that it will…

The post Corindus touts 1st Corpath GRX system installation outside the US appeared first on The Robot Report.

Corindus Vascular Robotics to test-drive HeartFlow’s 3D cardiac imaging tech

Corindus Vascular Robotics (OTC:CVRS), a Massachusetts-based surgical robotics company, plans to utilize technology that creates 3D images of arteries for evaluating patients. Company officials said they’d employ California-based HeartFlow’s FFRct Analysis in a case series of robotic-assisted percutaneous coronary interventions to evaluate the technology’s role in clinical decision support. The testing will be done at hospitals…

The post Corindus Vascular Robotics to test-drive HeartFlow’s 3D cardiac imaging tech appeared first on The Robot Report.

Corindus opens first international training center for CorPath GRX System

Corindus Vasular Robotics opened its first international CorPath GRX Robotic Center in Tokyo to educate cardiologists on robotic-assisted percutaneous coronary interventions, the company announced today. “The opening of the first international robotic center represents an important milestone in the process of bringing precision vascular robotics to patients and physicians in Japan and around the world,”…

The post Corindus opens first international training center for CorPath GRX System appeared first on The Robot Report.

Corindus launches post-approval study for CorPath GRX coronary system

Corindus Vascular Robotics announced the first patient enrollment in a post-market study of its second-generation CorPath GRX System, a robot-assisted system for percutaneous coronary interventions such as stenting. “Enrollment of the first patient in the Precision GRX registry is a major milestone for the company and we look forward to the participation of leading centers…

The post Corindus launches post-approval study for CorPath GRX coronary system appeared first on The Robot Report.